Source: http://texashhsc.swagit.com/play/10262018-781
Timestamp: 2019-09-20 14:36:48
Document Index: 478859210

Matched Legal Cases: ['art 1', 'art 1', 'art 2', 'art 2', 'art 1', 'art 2', 'art 1', 'art 2']

October 26, 2018 Drug Utilization Review Board - Texas Health and Human Services Commission
October 26, 2018 Drug Utilization Review Board
2. Approval of minutes from July 27, 2018 (vote required)
3. New member introductions and terms
4. Ethics policy refresher
5. Vice-chair election (vote required)
6. New business (Part 1 of 2) » - a. Androgenic agents b. Antibiotics, GI c. Antibiotics, topical d. Antibiotics, vaginal e. Antiemetics/Antivertigo agents f. Antifungals, oral g. Antifungals, topical h. Antihistamines, first generation i. Antiparasitics, topical j. Antipsychotics k. Antivirals, oral l. Antivirals, topical m. Bone resorption suppression and related agents n. Colony stimulating factors o. Cytokine and CAM antagonists
6. New business (Part 1 of 2) »
a. Androgenic agents
b. Antibiotics, GI
e. Antiemetics/Antivertigo agents
f. Antifungals, oral
g. Antifungals, topical
h. Antihistamines, first generation
i. Antiparasitics, topical
j. Antipsychotics
k. Antivirals, oral
o. Cytokine and CAM antagonists
6. New business (Part 2 of 2) » - p. Epinephrine, self-injected q. GI motility, chronic r. Growth hormone s. Hepatitis C agents t. Hypoglycemics, incretin mimetics/enhancers u. Hypoglycemics, insulin and related agents v. Hypoglycemics, meglitinides w. Hypoglycemics, metformins x. Hypoglycemics, SGLT2 y. Hypoglycemics, TZD z. Immunomodulators, atopic dermatitis aa. Macrolides/Ketolides bb. Ophthalmics, glaucoma agents cc. Opiate dependence treatments dd. Pediatric vitamin preparations ee. Penicillins ff. Tetracyclines a. Aimovig / Antimigraine agents, other b. Mircera / Erythropoiesis stimulating proteins c. Osmolex ER / Antiparkinson’s agents d. Retacrit / Erythropoiesis stimulating proteins e. Roxybond / Analgesics, Narcotics short
6. New business (Part 2 of 2) »
w. Hypoglycemics, metformins
x. Hypoglycemics, SGLT2
y. Hypoglycemics, TZD
z. Immunomodulators, atopic dermatitis
aa. Macrolides/Ketolides
bb. Ophthalmics, glaucoma agents
cc. Opiate dependence treatments
dd. Pediatric vitamin preparations
ee. Penicillins
ff. Tetracyclines
a. Aimovig / Antimigraine agents, other
b. Mircera / Erythropoiesis stimulating proteins
c. Osmolex ER / Antiparkinson’s agents
d. Retacrit / Erythropoiesis stimulating proteins
e. Roxybond / Analgesics, Narcotics short
7. Executive work session
8. Announcements of drugs recommended for the Medicaid PDL (vote required)
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Benzodiazepine anxiolytics and controlled sedative hypnotics ii. Diabetes disease management iii. Rheumatoid arthritis management b. Report on recent retrospective DUR intervention outcomes: i. Opioids during pregnancy ii. Polypharmacy iii. Stroke prevention c. Retrospective DUR proposals (vote required) i. Management of psychotropic drug in adults ii. Medication adherence
i. Benzodiazepine anxiolytics and controlled sedative hypnotics
ii. Diabetes disease management
iii. Rheumatoid arthritis management
i. Opioids during pregnancy
ii. Polypharmacy
iii. Stroke prevention
i. Management of psychotropic drug in adults
ii. Medication adherence
Items 10, 12 & 13 » - 10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) a. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria b. Cytokine and CAM antagonists - addition of Olumiant criteria 12. Adjourn 13. Next meeting date: January 25, 2019
Items 10, 12 & 13 »
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
a. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria
b. Cytokine and CAM antagonists - addition of Olumiant criteria
13. Next meeting date: January 25, 2019
What is the result of adding 'Eight' and "Nine"?
Additional Item 1 - 1. Call to order - 2. Approval of minutes from July 27, 2018 (vote required) - 3. New member introductions and terms - 4. Ethics policy refresher - 5. Vice-chair election (vote required) - 6. New business (Part 1 of 2) » - a. Androgenic agents ... Additional Item 2 - Additional Item 2 6. New business (Part 2 of 2) » - p. Epinephrine, self-inj... Additional Item 3 - Additional Item 3 7. Executive work session - 8. Announcements of drugs recommended for the Medicaid PDL (v... 9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, ... Items 10, 12 & 13 » - 10. Prospective prior authorization ...
'); // 480x380 to 640x360 jQuery("#segment_embed").val(' '); addthis.toolbox("#toolbox", {"data_track_addressbar":false, "data_track_clickback":false}, {"url":"http://texashhsc.swagit.com/play/10262018-781/" + the_item.mediaid}); // val = the_item.id; val = the_item.mediaid; jQuery("div[id=segment-" + val + "]").children('.extra').toggle(true); jQuery("div[id=segment-" + val + "]").children('.collapsed').children('.segment-title').css("font-weight", "normal") jQuery("div[id=segment-" + val + "]").children('.collapsed').css('hover', '#d7ddeb'); jQuery("div[id=segment-" + val + "]").children('.collapsed').css('background', '#edf0f6'); jQuery(".segment").css('border', 'none'); jQuery(".segment").css('border-bottom', '1px solid #cccccc'); jQuery("div[id=segment-" + val + "]").css('border', '2px solid #d7ddeb'); // seems to work in jwp // document.getElementById('tabs-1').scrollTop = document.getElementById(val).offsetTop - document.getElementById('tabs-1').offsetTop; }); var show_cc1 = false; var first_cc_load = true; /* player.on('play', function() { console.log('onplay'); if (seekFlag) { console.log('seeking'); seekFlag = false; player.currentTime(seekTo); } }); */ player.on('loadedmetadata', function() { console.log('onloadedmetadata'); if (seekFlag) { console.log('seeking'); seekFlag = false; player.currentTime(seekTo); } }); /* player.on('playing', function() { console.log('onplaying'); if (seekFlag) { console.log('seeking'); seekFlag = false; setTimeout(function(){ player.currentTime(seekTo); }, 1000) } }); */ /* // Add the event handler player.on('timeupdate', timeupdateHandler); //Handle the event then remove JUST this event listener on timeupdate function timeupdateHandler(evt) { if (seekFlag) { console.log('ontimeupdate & seek'); console.log('seeking'); seekFlag = false; } } */	player.on('playlistitem', function() { console.log('pli, setting first_cc_load'); first_cc_load = true; }); player.textTracks().on('change', function(one,two) { var tracks = player.textTracks(); for (var i = 0; i < tracks.length; i++) { var track = tracks[i]; if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'showing') { show_cc1 = true; } else if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'disabled') { show_cc1 = false; } } }); player.on('texttrackchange', function(one,two) { var tracks = player.textTracks(); console.log("ttc: " + first_cc_load); for (var i = 0; i < tracks.length; i++) { var track = tracks[i]; if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'disabled' && show_cc1 && first_cc_load) { this.ready(function(){ setTimeout(function(){ track.mode = 'showing'; }, 0); }); } } first_cc_load = false; }); // playlist-change-block player.on('playlistchange', function() { console.log('plc'); if (location.hash) { hash = location.hash.replace(/^#/, '') hash = hash.replace(/^&start=/, '') jQuery.each(playlist, function(item, value) { if (value['mediaid'] == hash) { player.playlist.currentItem(item); } }); } jQuery(window).hashchange( function(){ hash = location.hash.replace(/^#/, '') hash = hash.replace(/^&start=/, '') if (hash.match(/^i/)) { hash = hash.replace(/^i/, '') jQuery.each(playlist, function(item, value) { if (value['imported_mediaid'] == hash) { player.playlist.currentItem(item); } }); } else if (hash.match(/^t/)) { hash = hash.replace(/^t/, '') jwplayer("player").seek(hash); } else { jQuery.each(playlist, function(item, value) { if (value['mediaid'] == hash) { player.playlist.currentItem(item); } }); } }); // /playlist-change-block }); var playlist = [{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-782.360.mp4","title":"Additional Item 1 ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-782.480x360.jpg?r=2","mediaid":65,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-782.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-782.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-782.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-783.360.mp4","title":"1. Call to order ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-783.480x360.jpg?r=2","mediaid":2,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-783.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-783.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-783.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-784.360.mp4","title":"2. Approval of minutes from July 27, 2018 (vote required) ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-784.480x360.jpg?r=2","mediaid":3,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-784.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-784.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-784.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-785.360.mp4","title":"3. New member introductions and terms ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-785.480x360.jpg?r=2","mediaid":4,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-785.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-785.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-785.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-786.360.mp4","title":"4. Ethics policy refresher ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-786.480x360.jpg?r=2","mediaid":5,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-786.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-786.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-786.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-787.360.mp4","title":"5. Vice-chair election (vote required) ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-787.480x360.jpg?r=2","mediaid":6,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-787.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-787.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-787.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-788.360.mp4","title":"6. New business (Part 1 of 2)\n\u00a0\u00a0 \u00bb ","description":"a. Androgenic agents
","image":"https://stills.swagit.com/stills/2018/10/26/10262018-788.480x360.jpg?r=2","mediaid":7,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-788.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-788.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-788.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-796.360.mp4","title":"Additional Item 2 ","description":"Additional Item 2","image":"https://stills.swagit.com/stills/2018/10/26/10262018-796.480x360.jpg?r=2","mediaid":66,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-796.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-796.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-796.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-799.360.mp4","title":"6. New business (Part 2 of 2) \u00bb ","description":"p. Epinephrine, self-injected
z. Immunomodulators, atopic dermatitis\naa. Macrolides/Ketolides\nbb. Ophthalmics, glaucoma agents\ncc. Opiate dependence treatments\ndd. Pediatric vitamin preparations\nee. Penicillins\nff. Tetracyclines
c. Osmolex ER / Antiparkinson\u2019s agents
","image":"https://stills.swagit.com/stills/2018/10/26/10262018-799.480x360.jpg?r=2","mediaid":67,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-799.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-799.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-799.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-805.360.mp4","title":"Additional Item 3 ","description":"Additional Item 3","image":"https://stills.swagit.com/stills/2018/10/26/10262018-805.480x360.jpg?r=2","mediaid":87,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-805.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-805.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-805.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-789.360.mp4","title":"7. Executive work session\n\u00a0 ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-789.480x360.jpg?r=2","mediaid":39,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-789.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-789.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-789.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-790.360.mp4","title":"8. Announcements of drugs recommended for the Medicaid PDL (vote required) ","description":"","image":"https://stills.swagit.com/stills/2018/10/26/10262018-790.480x360.jpg?r=2","mediaid":40,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-790.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-790.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-790.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-791.360.mp4","title":"9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC \u00bb ","description":"a. Report on recent retrospective DUR interventions:
","image":"https://stills.swagit.com/stills/2018/10/26/10262018-791.480x360.jpg?r=2","mediaid":41,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-791.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-791.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-791.360.mp4/playlist.m3u8"}]},{"dfile":"https://media.swagit.com/podcasts/2018/10/26/10262018-792.360.mp4","title":"Items 10, 12 & 13 \u00bb ","description":"10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
","image":"https://stills.swagit.com/stills/2018/10/26/10262018-792.480x360.jpg?r=2","mediaid":53,"smimage":"https://stills.swagit.com/stills/2018/10/26/10262018-792.480x360.jpg?r=2","poster":"https://stills.swagit.com/stills/2018/10/26/10262018-792.480x360.jpg?r=2","sources":[{"type":"application/x-mpegURL","src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/10/26/10262018-792.360.mp4/playlist.m3u8"}]}]; player.playlist([]); player.playlist(playlist); // Play through the playlist automatically. player.playlist.autoadvance(0);